BMS Bets US$800 M Upfront That Flexus’ Preclinical IDO1 Inhibitor Is Best-in-Class

By Heather Cartwright

Pharma Deals Review: Vol 2015 Issue 3 (Table of Contents)

Published: 18 Mar-2015

DOI: 10.3833/pdr.v2015.i3.2098     ISSN: 1756-7874

Section: Mergers & Acquisitions



In by far the largest deal to date in the immuno-oncology sector in terms of upfront consideration, Bristol-Myers Squibb (BMS) has agreed to acquire start-up Flexus Biosciences for US$800 M plus up to US$450 M in development milestones that could be achieved within 3 years...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details